var data={"title":"Technetium Tc-99m gluceptate (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m gluceptate (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/482550?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=technetium-tc-99m-gluceptate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Technetium Tc-99m gluceptate (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46207139\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Draximage Gluceptate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13206421\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13206491\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Blood pool imaging: </b>IV: Stannous gluceptate complex: 0.03 mL/kg (16 micrograms Sn/kg) administered 10 to 30 minutes prior to 15 to 25 mCi (555 to 925 MBq) of sodium pertechnetate Tc 99m</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain imaging:</b> IV (based on 70 kg patient): 15 to 20 mCi (555 to 740 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal imaging:</b> IV (based on 70 kg patient): 10 to15 mCi (370 to 555 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801887\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801888\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49500864\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Draximage Gluceptate: Calcium gluceptate 25 mg per vial (5s) [to be combined with sodium pertechnetate Tc99m injection solution (not included)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46207140\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13253413\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For IV administration. Radiopharmaceutical; use appropriate precautions for handling and disposal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood pool imaging: Administer stannous gluceptate 10 to 30 minutes prior to injection of sodium pertechnetate Tc 99m by direct venipuncture; avoid heparinized catheter systems.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brain/kidney imaging: Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13206440\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Imaging agent:</b> Brain imaging agent used for evaluation of brain perfusion; kidney imaging agent used for evaluation of renal perfusion; cardiac blood pool imaging agent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13255274\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13206497\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">&lt;1%, postmarketing and/or case reports: Allergic dermatitis, dyspnea, erythema, flushing, hypersensitivity, nausea, pruritus, skin rash, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49500307\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to technetium Tc 99m gluceptate or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13206441\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Patients with renal disease may have delayed elimination, therefore decreasing quality of images.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other warnings/precautions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Blood pool imaging: Ensure patient is in stable cardiac condition prior to administering. Have resuscitative equipment readily available. If an imaging procedure with sodium pertechnetate Tc 99m is anticipated, that exam should be conducted prior to the use of stannous gluceptate or &gt;1 week after the use of sodium pertechnetate Tc 99m.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Brain/kidney imaging: Patients should be adequately hydrated prior to and after dosing; instruct patients to void frequently for 4 to 6 hours following administration to decrease radiation exposure to the bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13206473\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein 1999; ICRP 2000; Parker 2004). Pregnancy status should be determined in women of childbearing potential (Parker 2004). The manufacturer recommends that elective procedures done in women of reproductive potential be conducted within the first few (~10) days following onset of menses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17916861\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Technetium Tc 99m is excreted into breast milk. In a case report, a nursing mother was administered technetium Tc 99m glucoheptonate  550 mBq  IV 1 month after delivery. Peak activity in the breast milk was detected 3 hours after the injection and the calculated effective dose (0.085 mSv) was low enough that an interruption of breast-feeding would not have been necessary (Mountford 1987). The manufacturer recommends that nursing be discontinued. Most sources note that interruption of breast-feeding is not essential depending on the dose, but recommend stopping for 4 hours (Harding 1995; Mountford 1989; Stabin 2000; USNRC 1997) while other sources recommended stopping breast-feeding for 12 hours (ICRP 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Following the administration of a radiopharmaceutical, women with a well-established milk supply should pump at normal feeding times and discard the milk until breast-feeding may be resumed (Harding 1995; Mountford 1989). Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breast-feeding cannot be made (Mountford 1989; Rubow 1994). Elective diagnostic procedures should be delayed until breast-feeding has stopped (Parker 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (USNRC 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49500309\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49500310\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood pool imaging: Excretion: Urine (~28% after 24 hours); delayed in patients with ischemic heart disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brain/kidney imaging: Excretion: Urine (~70% after 24 hours); delayed in patients with renal impairment</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology (ACR) and Society for Pediatric Radiology (SPR), &quot;ACR-SPR Practice Guideline for the Performance of Adult and Pediatric Renal Scintigraphy,&quot; 2014. Available at http://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/Renal_Scintigraphy.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adelstein SJ, &quot;Administered Radionuclides in Pregnancy,&quot; <i>Teratology</i>, 1999, 59(4):236-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-gluceptate-united-states-not-available-drug-information/abstract-text/10331526/pubmed\" target=\"_blank\" id=\"10331526\">10331526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Draximage Gluceptate (technetium Tc 99m gluceptate) [product monograph]. Kirkland, Quebec, Canada: Jubilant DraxImage Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al, &quot;Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers,&quot; <i>Eur J Nucl Med</i>, 1995, 22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP), &quot;Pregnancy and Medical Radiation,&quot; <i>Ann ICRP</i>, 2000, 30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-gluceptate-united-states-not-available-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ and Coakley AJ, &quot;A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations,&quot; <i>Nucl Med Commun</i>, 1989, 10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-gluceptate-united-states-not-available-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ and Coakley AJ, &quot;Breast Milk Radioactivity Following Injection of 99Tcm-Pertechnetate and 99Tcm-Glucoheptonate,&quot;<i> Nucl Med Commun</i>, 1987, 8(10):839-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-gluceptate-united-states-not-available-drug-information/abstract-text/2829070/pubmed\" target=\"_blank\" id=\"2829070\">2829070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline for General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. Available at  http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al, &quot;The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry,&quot; <i>Eur J Nucl Med</i>, 1994, 21(2):144-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-gluceptate-united-states-not-available-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC), &quot;Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,&quot; 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16812 Version 39.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46207139\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13206421\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13206491\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22801887\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22801888\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49500864\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46207140\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13253413\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13206440\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13255274\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13206497\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F49500307\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13206441\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13206473\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17916861\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F49500309\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F49500310\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16812|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=technetium-tc-99m-gluceptate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Technetium Tc-99m gluceptate (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}